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 Prostaglandin E2–EP2–NF-kB signaling in
macrophages as a potential therapeutic target
for intracranial aneurysms
Tomohiro Aoki,1,2 Juhana Fro``sen,3,4,5 Miyuki Fukuda,1 Kana Bando,6,7 Go Shioi,7 Keiichi Tsuji,8
Eliisa Ollikainen,3 Kazuhiko Nozaki,8 Johanna Laakkonen,9 Shuh Narumiya1,2*
Intracranial aneurysms are common but are generally untreated, and their rupture can lead to subarachnoid
hemorrhage. Because of the poor prognosis associated with subarachnoid hemorrhage, preventing the progres-
sion of intracranial aneurysms is critically important. Intracranial aneurysms are caused by chronic inflammation of
the arterial wall due to macrophage infiltration triggered by monocyte chemoattractant protein-1 (MCP-1), macro-
phage activation mediated by the transcription factor nuclear factor kB (NF-kB), and inflammatory signaling involv-
ing prostaglandin E2 (PGE2) and prostaglandin E receptor subtype 2 (EP2). We correlated EP2 and cyclooxygenase-2
(COX-2) with macrophage infiltration in human intracranial aneurysm lesions. Monitoring the spatiotemporal pattern
of NF-kB activation during intracranial aneurysm development in mice showed that NF-kB was first activated in
macrophages in the adventitia and in endothelial cells and, subsequently, in the entire arterial wall. Mice with a
macrophage-specific deletion of Ptger2 (which encodes EP2) or macrophage-specific expression of an IkBa mutant
that restricts NF-kB activation had fewer intracranial aneurysms with reduced macrophage infiltration and NF-kB
activation. In cultured cells, EP2 signaling cooperated with tumor necrosis factor–a (TNF-a) to activate NF-kB and
synergistically induce the expression of proinflammatory genes, including Ptgs2 (encoding COX-2). EP2 signaling
also stabilized Ccl2 (encoding MCP-1) by activating the RNA-stabilizing protein HuR. Rats administered an EP2 an-
tagonist had reduced macrophage infiltration and intracranial aneurysm formation and progression. This signaling
pathway in macrophages thus facilitates intracranial aneurysm development by amplifying inflammation in intra-
cranial arteries. These results indicate that EP2 antagonists may therefore be a therapeutic alternative to surgery..sci
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Subarachnoid hemorrhage is the most severe form of cerebrovascular
disease and a fatal illness; up to 50% of patients die within 30 days
after the onset and 30% suffer from moderate to severe morbidity
(1). The main cause of subarachnoid hemorrhage is rupture of a
preexisting intracranial aneurysm, which affects 1 to 5% of the gen-
eral public (2, 3). Given the high prevalence and susceptibility to
subarachnoid hemorrhage, treatment of intracranial aneurysms to
prevent rupture is clinically important. Because of the lack of medical
therapy for intracranial aneurysms, only patients with “rupture-prone”
intracranial aneurysms, such as those that are more than 7 mm in
diameter or those that are located at specific bifurcation sites, are
surgically treated. Surgery carries the unavoidable risk of complica-
tions (4, 5), and the number of untreated patients remains very high.
Neither of these outcomes are desirable; less than half of intracranial
aneurysms [3050 lesions among 6697 unruptured intracranial aneu-
rysms (45.5%)] were surgically treated in a large Japanese cohort study(6). A safe and noninvasive medical therapy that prevents the progres-
sion and rupture of intracranial aneurysms is therefore urgently needed,
and to accomplish this goal, the mechanism responsible for formation
and progression of intracranial aneurysms must be elucidated.
Intracranial aneurysms are lesions that are histologically character-
ized by chronic inflammation and degenerative changes in the arterial
walls (7). These characteristics can be recapitulated in an animal
model, in which intracranial aneurysms are induced by renal hy-
pertension and unilateral ligation of the carotid artery (8, 9). Because
intracranial aneurysms occur at intracranial artery bifurcation sites
both clinically and in animal models, and computational simulation
of fluid hemodynamics shows a high wall shear stress at these sites,
it is thought that shear stress is a trigger for intracranial aneurysm
formation (10–12). High wall shear stress is thought to evoke an in-
flammatory response in endothelial cells, which then presumably
spreads to the whole arterial wall after macrophage recruitment and
secretion of proinflammatory factors (7, 13). Human intracranial an-
eurysms with high wall shear stress have more inflammatory cells in
their walls (14). The transcription factor nuclear factor kB (NF-kB)
appears to play a crucial role in these processes (7, 13, 15). The loss
of the NF-kB p50 subunit or pharmacological inhibition of its tran-
scriptional activity by intrathecal administration of decoy oligonucleo-
tides suppresses intracranial aneurysm formation and progression in
rodent models and suppresses inflammatory responses in the lesion,
verifying that NF-kB mediates inflammation in the arterial wall and is
critical for the formation and progression of intracranial aneurysms
(7, 15, 16). NF-kB and its downstream effectors are therefore potential
therapeutic targets for the treatment of intracranial aneurysms. How-
ever, because NF-kB signaling is also important in various physio-
logical processes, NF-kB–activating pathways that are restricted to1 of 17
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 the inflammatory setting within intracranial aneurysms would be an
ideal target.
Prostaglandins (PGs), including PGD2, PGE2, PGF2a, and PGI2,
and thromboxane A2 are arachidonic acid metabolites formed by the
sequential enzymatic action of cyclooxygenase (COX) and respective
synthases and exert their actions by acting on their cognate G protein
(heterotrimeric guanine nucleotide–binding protein)–coupled recep-
tors (17). Using mice deficient in individual PG receptors, we have
shown that PGE receptor subtype 2 (EP2) signaling is involved in
NF-kB activation and inflammation in the wall of intracranial aneu-
rysms (9, 18). An inducible isoform of COX, COX-2, membrane-bound
PGE synthase (mPGES-1), and EP2 all show increased abundance
in arterial walls during the formation of an intracranial aneurysm;
furthermore, the loss of EP2 suppresses NF-kB activation, inflamma-
tion, and intracranial aneurysm formation (18). However, the mech-
anism by which EP2 signaling is linked to NF-kB activation and the
types of cells in which this pathway operates remain obscure. More-
over, it remains unclear whether pharmacological manipulation of this
pathway would have the desired therapeutic effect. Here, we found
that EP2 signaling directly activates NF-kB p50/p65, which cooperates
with tumor necrosis factor–a (TNF-a)–activated NF-kB and synergis-
tically induces the expression of various inflammation-related genes
including Ptgs2 (which encodes COX-2). In addition, we show that
deletion of Ptger2 (which encodes EP2) and suppression of NF-kB
specifically in macrophages inhibited macrophage infiltration and pre-
vented intracranial aneurysm formation. We further found that admin-
istration of an EP2 antagonist prevents not only the formation but also
the progression of intracranial aneurysms. Because EP2 is abundant in
macrophages in human intracranial aneurysm lesions, this suggests that
EP2 antagonism is a promising therapeutic strategy to prevent the pro-
gression of intracranial aneurysms. o
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COX-2 and EP2 are associated with macrophage infiltration
in the wall of intracranial aneurysms in humans
Previous studies in animal models have shown that NF-kB signaling
in macrophages plays a crucial role in the inflammation underlying
intracranial aneurysm pathogenesis and implicate EP2 in the inflam-
matory processes (13, 15, 18, 19). We first aimed to clarify the clinical
relevance of these findings.We used immunostaining to assess EP2 and
COX-2 abundance in human intracranial aneurysm lesions (Fig. 1A) in
surgical samples obtained from 36 patients (20). We correlated the
abundance of these proteins with other parameters of inflammation,
particularly macrophage infiltration into the walls of the intracranial
aneurysms. We performed immunostaining for CD68 to detect
macrophages and for COX-2 and EP2 in adjacent tissue sections from
aneurysm lesions (21, 22). Both EP2 and COX-2 were detected in all
layers of the intracranial aneurysm wall, including the endothelial layer
and the adventitia. In addition, EP2 and COX-2 immunostaining
appeared as numerous puncta in the inner half of the media, where
smooth muscle cells were lost because of tissue degeneration (Fig. 1A,
left and middle); this smooth muscle loss is characteristic of ruptured
intracranial aneurysms (22). CD68-positive cells were also scattered in
a similar pattern in the media and the adventitia, suggesting macro-
phage infiltration in these regions (Fig. 1A, right). When the density
of EP2 and COX-2 signals in the whole arterial wall was scored in each
sample (fig. S1), and compared to the number of CD68-positivemacro-
phages in adjacent sections, the EP2 and COX-2 signal scores in theAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017lesion correlated both positively and significantly with the number of
infiltrated macrophages (Fig. 1B). Furthermore, double immunohisto-
chemistry showed that the EP2 signals largely colocalizedwith those for
CD68 in the adventitia and media (Fig. 1C). In addition, EP2 signals
colocalized with the endothelial cell marker CD31 in the endothelium
andwith the smoothmuscle cellmarkera–smoothmuscle actin in the
media where degenerative change was limited (fig. S2, A to F).
NF-kB activation is spatiotemporally regulated in
intracranial aneurysm lesions
Our finding that EP2 was present in macrophages, endothelial cells,
and smooth muscle cells in human intracranial aneurysm tissue sam-
ples raised the question about the time course of these changes in EP2A
B
C
EP2 signal score COX-2 signal score
Fig. 1. EP2 and COX-2 distribution in human intracranial aneurysms. (A) Adja-
cent tissue sections were prepared from unruptured or ruptured human intracranial
aneurysm samples and stained for EP2 (left), COX-2 (middle), and CD68 (right, with
Oil Red O background staining). Representative image from ruptured intracranial an-
eurysm is shown. Adv., adventitia; Med., media; EC, endothelial cell layer. Scale bar,
100 mm. (B) The intensity of EP2 and COX-2 immunostaining was scored according to
the criteria described in fig. S1, and the correlation of signal intensity with the num-
ber of CD68-positive macrophages in the lesion was examined using the Spearman
rank correlation test. Red and blue circles indicate data from ruptured and unrup-
tured aneurysms, respectively. n = 36 human intracranial aneurysm specimens.
(C) Colocalization of EP2 signals (red) with those of CD68 (green) in the adventitia
and media. Merged images with nuclear 4′,6-diamidino-2-phenylindole (DAPI)
staining are also shown in the left panel. Images with higher magnification
corresponding to the square in the upper panel are shown in the lower panels.
n = 14 human intracranial aneurysm samples. Scale bar, 100 mm.2 of 17
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 abundance during intracranial aneurysm development. Given the cru-
cial role of NF-kB as a key mediator of inflammation in intracranial
aneurysm lesions (7, 15) and our previous finding that EP2 signaling
activates NF-kB in primary cultured endothelial cells in vitro (18), we
wanted to follow the course of inflammation during intracranial an-
eurysm development by monitoring NF-kB activation in the arterial
walls of intact animals. To this end, we made a construct encoding a
derivative of red fluorescent protein (RFP), Timer-1 (23), with consensus
NF-kB binding sites in its promoter region (fig. S3A). Expression of this
Timer-1 construct yielded potent RFP signals in response to TNF-a in
human embryonic kidney (HEK) 293 cells (fig. S3B). We then generated
a transgenic mouse line expressing this construct and subjected the mice
to NF-kB–activating stimuli. Intraperitoneal injection of lipopolysac-
charide (LPS) induced Timer-1 protein expression in the liver of thesemice,
and dextran sodium sulfate (DSS)–induced colitis induced Timer-1 ex-
pression in the colon (fig. S3, C and D). We then induced intracranial
aneurysm formation in this line of NF-kB reporter mice. Before intra-
cranial aneurysm induction, Timer-1 signals were not detected at the
bifurcation sites of intracranial arteries (Fig. 2A). NF-kB activation, as
assessed by Timer-1 expression, was first detected on the luminal sur-
face and the adventitia of the arterial wall 2 weeks after intracranial an-
eurysm induction and spread to neighboring regions with increasing
intensity by 4 weeks. At this time point, Timer-1 signals in the adven-
titia colocalized with those for the macrophage marker F4/80 and those
at the luminal surface with the endothelial marker CD31 (fig. S4), sug-
gesting that NF-kB was activated in macrophages infiltrating into the
adventitia and in endothelial cells at this stage of intracranial aneu-
rysm formation. At 8 weeks after induction, NF-kB activation was
observed in the whole arterial wall (Fig. 2A), and coimmunofluores-
cence analysis indicated that it also occurred in smooth muscle cells in
the media, macrophages in the adventitia, and endothelial cells (fig. S4).
Once triggered, NF-kB activation, as monitored by Timer-1 expression,
was sustained in the intracranial aneurysm lesions until at least 32 weeks
(Fig. 2A). However, because intracranial aneurysm progression is
limited in this mouse model and the smooth muscle layer is almost in-
tact during the experimental period (8, 24), we did not monitor NF-kB
activation in the intracranial aneurysm walls up to the stage of excessive
degeneration of the media and loss of medial smooth muscle cells, as
was detected in human intracranial aneurysms (Fig. 1).
PGE2-EP2 signaling in macrophages sustains inflammation,
leading to intracranial aneurysm formation
EP2 signaling activates NF-kB in primary cultured endothelial cells
in vitro (18). To determine whether EP2 signaling also activated NF-kB
activation in vivo in intracranial aneurysm lesions, we used Ptger2-
deficient mice (25) crossed with NF-kB reporter mice. Ptger2 deficien-
cy suppressed NF-kB activation in intracranial arteries 4 and 8 weeks
after intracranial aneurysm induction in a gene dosage–dependent
manner (Fig. 2B). These data implied that EP2 signaling was involved
in NF-kB activation in endothelial cells and macrophages at the begin-
ning of intracranial aneurysm formation as well as in the entire arterial
wall at later stages of intracranial aneurysm formation.
To determine the cell type that was important for EP2-induced
NF-kB activation and in intracranial aneurysm formation, we gener-
ated Ptger2flox/flox mice. Using the loxP-Cre recombinase system, we de-
leted the first exon of Ptger2, which encodes the first to the middle of
the sixth transmembrane domains of the EP2 protein. The mice pro-
duced by this approach had a similar genotype as the Ptger2-deficient
mice we generated previously (fig. S5, A to C) (25). Cre-dependentAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017deletion of the first exon of Ptger2 was confirmed by direct sequenc-
ing of genomic DNA from the kidneys of Ptger2flox/flox-EIIa-Cre
mouse. Macrophage- or endothelial cell–specific deletion of Ptger2
was then achieved by crossing Ptger2flox/flox mice with Lyz2-Cre mice
(Ptger2f/fLyz2Cre mice), which express Cre specifically in macrophages
under the control of the Lyz2 (which encodes lysozyme 2) promoter,
or Cdh5-Cre mice (Ptger2f/fCdh5Cre mice), which express Cre specif-
ically in endothelial cells under the control of Cdh5 (which encodes
VE-cadherin) promoter, respectively. We first assessed NF-kB activa-
tion by performing immunohistochemistry for the NF-kB p65 subunit
phosphorylated at Ser536 in these two lines of transgenic mice after
intracranial aneurysm induction. The macrophage-specific deletion
of Ptger2 prevented NF-kB activation in endothelial cells 2 weeks after
surgical manipulation, an early stage of intracranial aneurysm formation
(Fig. 2C), and almost abolished NF-kB activation in whole intracranial
arterial walls at the later stage (20 weeks after surgical manipulation)
(Fig. 2D). Notably, macrophage-specific deletion of Ptger2 suppressed
the abundance of proteins regulated by NF-kB activation, namely, mono-
cyte chemoattractant protein-1 (MCP-1) and COX-2, in the adventitia of
intracranial aneurysm lesions where macrophages accumulated (fig. S6),
suggesting that regulation of NF-kB activation by EP2 signaling occurred
in macrophages in vivo. In contrast, Ptger2 deletion specifically in endo-
thelial cells (Ptger2f/fCdh5Cre mice) abolished the signals in the endothe-
lium but did not affect NF-kB activation in the adventitia at 20 weeks
(Fig. 2D).
Because these data suggested that EP2 signaling in endothelial cells
and macrophages contributes to the inflammatory responses in these
cell types at the initial stages and that EP2 signaling in macrophages
may have sustained effects on inflammation in arterial walls, we next
examined the contribution of the signaling in each cell type to intra-
cranial aneurysm formation. Because the mouse model of intracranial
aneurysm shows limited lesion progression and does not induce out-
ward bulging of arterial walls, which is typically observed at the ad-
vanced stage (8), we evaluated intracranial aneurysm formation by
examining breakage of the lamina elastica and also assessed macro-
phage infiltration using immunohistochemistry for F4/80-positive
cells. Twenty weeks after surgical manipulation, Ptger2f/fLyz2Cre mice,
but not Ptger2f/fCdh5Cre mice, had significantly less intracranial aneu-
rysm formation (Fig. 2E), which was accompanied by suppression of
NF-kB activation and macrophage recruitment to intracranial aneu-
rysm lesions (Fig. 2, D and F). Deficiency of Ptger2 specifically in en-
dothelial cells did not affect intracranial aneurysm formation (Fig. 2E)
or macrophage infiltration of the lesions (Fig. 2F). These data suggest
that EP2-mediated NF-kB activation in macrophages, but not in en-
dothelial cells, specifically contributes to intracranial aneurysm forma-
tion in vivo.
NF-kB activation in macrophages is critical for intracranial
aneurysm formation
To corroborate the role of macrophage signaling in intracranial an-
eurysm inflammation and to examine whether NF-kB activation spe-
cifically in macrophages is critical to intracranial aneurysm formation,
we established a mouse line in which a mutated form of IkBa (S32A/
S36A-IkBa) was expressed under the control of Cre recombinase.
Expression of this IkB mutant protein could easily be monitored be-
cause of its fusion with mCherry (Fig. 3A and fig. S7, A to C). S32A/
S36A-IkBa is a superrepressor of NF-kB (26) because it is resistant to
phosphorylation-dependent degradation, thereby interfering with the
nuclear translocation of NF-kB. The Cre-dependent expression of the3 of 17
SC I ENCE S I GNAL ING | R E S EARCH ART I C L EIkB mutant, its resistance to degradation under NF-kB–activating
conditions, and its inhibitory effect on NF-kB activation were con-
firmed in vitro either in HEK293 cells or in a stable NF-kB reporter
HEK293 cell line [a cell line that expresses green fluorescent protein
(GFP) under the transcriptional control of NF-kB] stimulated with
TNF-a (fig. S8, A to C). The Cre-dependent expression of the IkB
mutant was further confirmed by transfecting a Cre-expressing plas-
mid into primary intraperitoneal macrophages isolated from trans-Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017genic mice or by injecting a Cre-expressing plasmid into the femoral
muscle of this mouse line (fig. S8, D and E). We crossed these IkB
mutant mice with either Lyz2-Cre mice or Cdh5-Cre mice. IkB mutant–
Lyz2Cre mice and IkB mutant–Cdh5Cre mice (figs. S9, A and B, and
S10A) showed expression of the IkB mutant protein, as assessed by
mCherry expression, specifically in F4/80-positive macrophages (fig.
S9, A and C) and CD31-positive endothelial cells (fig. S10, B and
C), respectively. When intracranial aneurysms were induced in these o
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 mice, the incidence of intracranial aneurysms
in the IkB mutant–Cdh5Cre mice was compa-
rable to that in their littermates, whereas the
IkB mutant–Lyz2Cre mice had a significantly
lower incidence of intracranial aneurysms
and also demonstrated reduced macrophage
infiltration compared to their littermates (Fig.
3A) in the absence of changes in systemic
blood pressure (fig. S11, A and B). These data
are consistent with the effect of cell type–
specific deletion of Ptger2 on the sustained
activation ofNF-kB, as assessed by Timer-1 ex-
pression, in the whole arterial wall (Fig. 2, C
and D). As was observed in the Ptger2f/fLyz2Cre
mice (Fig. 2D), NF-kB activation, as assessed
by immunostaining for phosphorylated p65,
was suppressed in the whole arterial wall in
the IkB mutant–Lyz2Cre mice compared to
their littermates (Fig. 3B). Quantitative real-
time polymerase chain reaction (RT-PCR)
analysis revealed that intracranial aneurysm
induction increased the expression of Ccl2
and Ptgs2, which encode two NF-kB–induced
proinflammatory proteins that are involved in
intracranial aneurysm formation (18, 19, 27).
The increase in the expression of these two
proinflammatory factors was ablated in macro-
phages expressing the IkB mutant (Fig. 3C).
These findings were consistent with the pres-
ence of MCP-1 in macrophages infiltrating
the intracranial aneurysm lesions, which was
abolished in IkB mutant–Lyz2Cre mice (Fig.
3D). These results indicate that NF-kB activation
in macrophages promotes inflammation in
the whole arterial wall and critically contributes
to intracranial aneurysm formation, at least
partly, by forming a self-recruiting loop consist-
ing of macrophages secreting their own chemo-
attractant, MCP-1.
EP2 signaling directly activates NF-kB and
synergistically induces NF-kB–dependent
gene expression with TNF-a through a
PGE2–EP2–NF-kB–COX-2–positive
feedback loop
To examine whether EP2 stimulation could
directly induce NF-kB activation and to deter-
mine the underlying mechanism, we generated
HEK293 cells stably expressing mouse EP2 (fig.
S12A) and confirmedEP2 expression by immuno-
histochemistry (fig. S12B) and by increases inBA
C D
E F
Fig. 2. EP2 signaling in macrophages sustains inflammation in intracranial aneurysm walls and intracranial
aneurysm induction. (A) Time course of NF-kB activation in intracranial aneurysm walls monitored by Timer-1 ex-
pression. Arrows and arrowheads indicate signals in endothelial cells and macrophages, respectively. Scale bars,
20 mm. Representative images from three slices per mouse (five mice for 0, 1, 2, 3, 4, 8, and 20 weeks; three mice for
27 and 32 weeks) are shown. (B) NF-kB activation in intracranial aneurysm walls was monitored in Ptger2+/− and
Ptger2−/− NF-kB reporter mice 4 or 8 weeks after intracranial aneurysm induction. Scale bars, 20 mm. Representative
images frommice (n = 5) from each genotype and each time point from three independent experiments are shown.
(C and D) NF-kB activation examined by staining for phosphorylated p65 (Ser536; p-p65) in intracranial aneurysm
lesions in Ptger2f/fLyz2Cre mice at an early stage (2 weeks) (C) and in Ptger2f/fLyz2Cre and Ptger2f/fCdh5Cre mice at a
late stage (20 weeks) (D) of intracranial aneurysm formation. In (C), sections were also stained for the endothelial cell
marker CD31. Nuclear staining with DAPI (blue) is also shown in merged images. Representative images are shown
(n = 4 mice for each genotype and time point from three independent experiments). Scale bars, 30 mm (C) and
40 mm (D). (E and F) Intracranial aneurysm incidence (E) and macrophage infiltration (F) in Ptger2f/fLyz2Cre and
Ptger2f/fCdh5Cre mice 5 months after intracranial aneurysm induction. The numbers of animals used are shown
in parentheses. Statistical analysis was performed using Fisher’s exact test (E) or a Mann-Whitney test (F). Bars in
(F) indicate means ± SEM.4 of 17
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 adenosine 3′,5′-monophosphate (cAMP) in response
to the selective EP2 agonist ONO-AE1-259 (fig.
S12C) (28). Stimulation with ONO-AE1-259 signifi-
cantly increased the nuclear translocation of the
canonical NF-kB subunits p50 and p65, but not
that of c-Rel (Fig. 4A). ONO-AE1-259 also induced
the NF-kB–dependent expression of an NF-kB re-
porter in HEK293-EP2 cells (fig. S13A). These find-
ings are consistent with our previous in vivo findings
showing that the p50-p65 complex is activated in in-
tracranial arteries after aneurysm induction (15) and
that Ptger2 deficiency decreases p65 phosphorylation
in intracranial arteries (18). We next examined whether
EP2 signaling affected phosphorylation of Ser337 in
p50, an event that is critical for DNA binding (29, 30).
ONO-AE1-259 increased the phosphorylation of this
site in a time- and concentration-dependent manner
(Fig. 4B), and this was mimicked by the cAMP analog
dibutyryl-cAMP (db-cAMP), and inhibited by the
protein kinase A (PKA) inhibitor H-89 (fig. S13B),
indicating that EP2 simulation mobilizes the cAMP-
PKA pathway to phosphorylate the p50 subunit. ONO-
AE1-259 also increased phosphorylation of NF-kB
p65 at Ser536 in a time-dependent manner (Fig. 4C).
These results suggest that EP2 signaling activates
the canonical NF-kB signaling cascade by inducing
the phosphorylation of the p50 and p65 subunits.
However, this activation was much weaker than that
induced by cytokines such as TNF-a (Fig. 4C and
fig. S13, A and C), which led us to hypothesize that
NF-kB activation by EP2 stimulation synergizes with
other signaling pathways to amplify expression of
NF-kB target genes. We chose to test this synergism
hypothesis using TNF-a because TNF-a signaling al-
so contributes to intracranial aneurysm formation
(31–33). Treatment of primary macrophages isolated
from the intraperitoneal cavity with ONO-AE1-259
and TNF-a potently amplified the expression of TNF-
a–induced, NF-kB–dependent genes, including Il6
[which encodes interleukin-6 (IL-6)], Il1b (which
encodes IL-1b), Ptgs2, and Nos2 (which encodes
inducible nitric oxide synthase) (Fig. 4D and fig.
S13D). Consistent with NF-kB activation by EP2 stim-
ulation, NF-kB inhibitor IV (34–36) significantly atte-
nuated the amplifying effect of ONO-AE1-259 on
TNF-a–induced gene expression (fig. S14, A to D).
We further examined the molecular mechanism un-
derlying the synergy between EP2 and TNF-a by using
HEK293-EP2 cells expressing a Ptgs2 promoter–
containing luciferase reporter. We found that ONO-
AE1-259 increased luciferase activity and Ptgs2 expres-
sion synergistically with TNF-a (Fig. 4E and fig.
S15A). Because both EP2 and TNF-a signaling activate
NF-kB, and the Ptgs2 promoter contains two consen-
sus NF-kB binding sites (the distal NF-kB site is lo-
cated about −447 position and the proximal NF-kB
site is about −223 position from the transcription
initiation site), we examined NF-kB binding sites that
responded to each signaling stimulus. ONO-AE1-259D
B
A
C
Fig. 3. NF-kB activation in macrophages is required for sustained inflammation in intracranial
arteries and intracranial aneurysm formation. (A) Intracranial aneurysm incidence and macrophage
infiltration in macrophage-specific Lyz2-Cre and endothelial cell–specific Cdh5-Cre IkB mutant mice 5 months
after intracranial aneurysm induction. The IkB mutant construct, the intracranial aneurysm incidence, and
macrophage infiltration are shown. The numbers of animals used are shown in parentheses. Statistical anal-
ysis was performed using Fisher’s exact test (left) or a Mann-Whitney test (right). Bars in the right panel
indicate means ± SEM. (B and C) Suppression of NF-kB activation (B) and increases in Ccl2 and Ptgs2 expres-
sion (C) in intracranial aneurysm lesions in IkB mutant–Lyz2Cre mice. Samples were collected for analyses
from mice that were not operated on as a control (0 M) and mice 5 months after intracranial aneurysm
induction (5 M). Immunostaining for the phosphorylated form of p65 (Ser536; p-p65) representative of five
samples from each genotype is shown in (B), and quantitative RT-PCR analyses for Ccl2 and Ptgs2 are shown
in (C) (n = 8 littermates or 4 Tg/Cre mice; Kruskal-Wallis test). Scale bars, 30 mm. (D) MCP-1 abundance in
intracranial aneurysm walls in IkB mutant–Lyz2Cre mice. Immunostaining for F4/80 (green) and MCP-1 (red),
nuclear staining by DAPI, and merged images are shown (n = 5 mice for each genotype from three
independent experiments). Scale bars, 20 mm. In the lower panels, sketch of the aneurysm lesion is shown
as reference.5 of 17
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Fig. 4. Synergistic activation of NF-kB and NF-kB–induced gene expression by EP2 and TNF-a signaling. (A to C) Nuclear translocation and time- and dose-
dependent phosphorylation of p50/p65 NF-kB subunits after EP2 stimulation. HEK293 cells stably expressing EP2 (HEK293-EP2 cells) were stimulated with ONO-AE1-259
for the indicated times or at the indicated concentrations. (A) Nuclear translocation was assessed using a DNA binding enzyme-linked immunosorbent assay (n = 3
biological replicates, Mann-Whitney test). (B) p50 (Ser337) phosphorylation was analyzed, and a representative Western blot is shown with a-tubulin as an internal
control (n = 3 independent experiments). (C) p65 (Ser536) phosphorylation was analyzed with a-tubulin as an internal control and with TNF-a (TNF) stimulation as a positive
control (n = 3 independent experiments). (D) Peritoneal macrophages were stimulated with TNF-a alone or with ONO-AE1-259, and the expression of NF-kB–regulated genes
was analyzed by PCR array analysis (n = 3 biological replicates, Mann-Whitney test). (E to G) HEK293-EP2 cells transfected with the Ptgs2 promoter–luciferase construct were
stimulated with TNF-a, ONO-AE1-259, or both. Cells were assayed for luciferase activity (n = 5 biological replicates, Kruskal-Wallis test) (E), ChIP assay using an antibody specific
for the p65 subunit (n = 3 biological replicates, Mann-Whitney test) (F), and Re-ChIP assay using antibodies specific for p65 and Sp1 (n = 6 biological replicates, Mann-Whitney
test) (G).Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017 6 of 17
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 enhanced the luciferase activity of a construct containing the distal NF-
kB site, and mutation or deletion of this site significantly attenuated the
ONO-AE1-259–induced increase in Ptgs2 promoter activity (fig. S15B).
In contrast, TNF-a stimulation enhanced the luciferase activity of the
construct containing the proximal NF-kB site, and deletion of this site
attenuated TNF-a action (fig. S15C). Consistent with these findings,
chromatin immunoprecipitation (ChIP) analysis revealed that ONO-
AE1-259 treatment resulted in selective binding of p65 to the distal NF-
kB site, whereas p65 activated by TNF-a signaling bound to the proximal
NF-kB site to a greater extent (Fig. 4F). Although the precise mech-
anism by which NF-kB activated by different signaling events leads to
binding to different NF-kB sites is not clear, we suspected that differ-
ences in the composition of the transcription factor complex could be
important. We noted that both the DNA binding and transcriptional
activity of Sp1 were activated by TNF-a stimulation but not by EP2
stimulation (fig. S16, A and B). Pharmacological inhibition of Sp1
using mithramycin or depletion of Sp1 by RNA interference (RNAi)
inhibited the enhancing effect of TNF-a or the synergistic effect of
EP2 and TNF-a on Ptgs2 promoter–driven luciferase activity; in con-
trast, overexpression of Sp1 enhanced luciferase activity under these
conditions (fig. S16, C to E). These data suggest the formation of a
transcription factor complex containing p50, p65, and Sp1. To corrobo-
rate this idea, we performed Re-ChIP assays in which transcriptional
complexes were first immunoprecipitated with an antibody specific for
p65 and then with an antibody for Sp1. Immunoprecipitation of the
Ptgs2 promoter DNA was then examined by quantitative PCR analysis.
Chromatin fragments corresponding to the Sp1 binding site, the distal
NF-kB site, and the proximal NF-kB site of the Ptgs2 promoter were
all significantly enriched by sequential immunoprecipitation (Fig. 4G).
In addition, the DNA binding activity of Sp1 was increased in rat in-
tracranial arterial samples 1 month after intracranial aneurysm induc-
tion without changes in its mRNA expression (fig. S16, F and G).
Together, these data suggested the formation of a transcription factor
complex containing p50-p65-Sp1 on the promoter region of Ptgs2 in
vitro and in vivo. Given that COX-2 initiates PGE2 biosynthesis, these
findings revealed a positive feedback loop of the PGE2–EP2–NF-kB–
COX-2 pathway to amplify PG-mediated, NF-kB–dependent inflam-
mation by induction of COX-2. The presence of such an amplification
loop has been suggested for intracranial aneurysm formation in vivo
(9, 13, 18) and is consistent with our findings (Figs. 2 and 3).
EP2 signaling stabilizes Ccl2 mRNA by activating the RNA
binding protein HuR
Because MCP-1 induction in intracranial aneurysm lesions could lead
to the formation of a self-amplification loop that exacerbates inflam-
mation by recruiting more macrophages into the lesion, thereby facil-
itating intracranial aneurysm progression (Fig. 3) (7, 9, 19, 27), we
next examined whether EP2 signaling could induce Ccl2 (which en-
codes MCP-1) expression synergistically with TNF-a, as was observed
for Ptgs2 expression. ONO-AE1-259 stimulation alone failed to induce
Ccl2mRNA expression, but it significantly enhanced the expression of
the gene when added with TNF-a compared to cells that were stimu-
lated only with TNF-a (Fig. 5A). Ccl2mRNA is stabilized by the RNA
binding protein HuR (37). To examine whether posttranscriptional
modifications might be involved in the amplifying action of ONO-
AE1-259 on Ccl2 expression, Ccl2 mRNA expression was induced
by TNF-a in HEK293-EP2 cells before the transcriptional inhibitor
actinomycin D was added. We found that ONO-AE1-259 significantly
delayed the decay of Ccl2 mRNA (Fig. 5B) but not that of Ptgs2Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017mRNA (fig. S17A), suggesting that EP2 signaling stabilized Ccl2
mRNA to amplify inflammation through macrophage infiltration. To
further confirm the stabilizing effect of EP2 signaling on Ccl2 mRNA
expression, we performed luciferase reporter assays using a construct
containing the 3′ untranslated region (3′UTR) of the human Ccl2mRNA
[355 base pairs (bp)] (Fig. 5C); costimulation with interferon-g (IFN-g)
and TNF-a were used as positive controls (37). Consistent with the
above results, ONO-AE1-259 significantly enhanced the activity of
the luciferase reporter in EP2-expressing HEK293 cells (Fig. 5C). We
next assessed the involvement of HuR in the effect of ONO-AE1-259.
Depletion of Elavl1 (which encodes HuR) by RNAi or removal of the
HuR-binding site from the 3′UTR of Ccl2 in the luciferase construct
attenuated the effect of ONO-AE1-259 on the promoter activity of the
Ccl2 luciferase reporter (Fig. 5, D and E, and fig. S17B), confirming the
involvement of HuR in the effect of EP2 signaling on the stabilization
of Ccl2 mRNA. HuR translocates from the nucleus to the cytoplasm
to stabilize its target mRNAs (38–40). As expected from the above
results, nuclear-to-cytoplasmic translocation of HuR was induced by
ONO-AE1-259 treatment, as shown by Western blot analysis of sub-
cellular fractions (fig. S17C). We then examined whether EP2 stim-
ulation promoted the binding of HuR to the 3′UTR of the Ccl2mRNA
by performing quantitative RT-PCR analysis on HuR immunoprecipi-
tates of nuclear extracts prepared fromHEK293-EP2 cells. We found that
Ccl2 mRNA was enriched in HuR immunoprecipitates compared with
control immunoglobulin G (IgG) immunoprecipitates and that ONO-
AE1-259 treatment increased the enrichment of Ccl2 more than 10-fold
(Fig. 5F), confirming that EP2 signaling facilitated HuR binding to the
3′UTR of the Ccl2 gene. p38 mitogen-activated protein kinase (MAPK)
signaling is involved in the nuclear-to-cytoplasmic translocation of HuR
(38). EP2 signaling activated p38 MAPK (fig. S18, A and B), and the
p38 MAPK inhibitors SB202190 or SB239063 attenuated the effect of
ONO-AE1-259 on the activity of the Ccl2 luciferase reporter (fig. S17D).
This effect was mimicked by leptomycin B, which inhibits nuclear export
of proteins (fig. S17D). Together, these data support a role for p38 MAPK
activated by EP2 signaling in theHuR-mediated stabilization ofCcl2mRNA.
Oral administration of the selective EP2 antagonist PF-
04418948 suppressed intracranial aneurysm progression
Because EP2 functions as a node for inflammatory responses respon-
sible for intracranial aneurysm formation, we next examined the
potential of pharmacological manipulation of EP2 as a therapeutic
measure to treat intracranial aneurysms. We noted that, in the micro-
array analysis using the ring of Willis from rats with induced intra-
cranial aneurysms, Ptger2 was among the genes with the greatest
increase in expression in lesions compared to normal (table S1 and
data file S1), which further supports the potential of EP2 as a therapeutic
target. The selective EP2 antagonist PF-04418948 (41) dose-dependently
decreased the size of induced intracranial aneurysms at 3 weeks (Fig. 6A),
and furthermore, it reduced degenerative changes in themedia, such as thin-
ning of themedial smoothmuscle cell layer and preservation of a–smooth
muscle actin–positive cells, without significantly affecting systemic
blood pressure (fig. S19, A and B). Pharmacological inhibition of EP2
also prevented increases in the phosphorylation of NF-kB p65 at Ser536
and in the abundance of COX-2 and MCP-1 (Fig. 6B) and suppressed
macrophage infiltration into intracranial aneurysm lesions (Fig. 6C).
Because intracranial aneurysms in most patients are usually found
during magnetic resonance imaging (MRI) examination of the brain
(6, 42), a drug therapy for intracranial aneurysms must be able to tar-
get preexisting intracranial aneurysms. In patients with unruptured7 of 17
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 intracranial aneurysms, the annual rate of rupture is positively corre-
lated with the size of the aneurysm (6). We therefore examined the
therapeutic effects of PF-04418948 on preexisting intracranial aneur-
ysms with prevention of further enlargement as an endpoint. Rate of
aneurysm rupture was not chosen as the endpoint because only a very
small number of the intracranial aneurysms induced in this rat model
spontaneously rupture (about 1% per month) (8). In the vehicle-treated
group, intracranial aneurysms progressively enlarged during the follow-
up period (Fig. 6D). In contrast, PF-04418948 significantly suppressed
the further enlargement of the induced intracranial aneurysms without
influencing systemic blood pressure (Fig. 6D and fig. S19C). Histologi-
cally, treatment with PF-04418948 suppressed media thinning (fig. S19D)
and macrophage infiltration (Fig. 6E). These data corroborate theAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017potential of EP2 as a therapeutic target for intra-
cranial aneurysms and suggest that an EP2 antag-
onist could be a promising drug candidate for
treatment of human intracranial aneurysms.DISCUSSION
Here, we have used clinical tissue samples taken from
intracranial aneurysm patients, transgenic animal
models, and transfected cultured cells to examine
the mechanism underlying intracranial aneurysm
formation. We focused on the COX-2–PGE2–EP2
signaling pathway, because we have previously
found that Ptger2 deficiency suppresses intracranial
aneurysm formation and that NF-kB–mediated in-
flammation occurs in the mouse intracranial aneu-
rysm model (18). We found a positive correlation
between EP2 abundance and macrophage infiltra-
tion in the human intracranial aneurysm tissue
samples (Fig. 1). We discovered that EP2 signaling
in macrophages sustained the NF-kB–mediated in-
flammation in the lesion and induced intracranial
aneurysm formation. NF-kB activation in macro-
phages was crucial for intracranial aneurysm for-
mation and for the inflammatory response. Our
study also revealed that EP2 signaling directly acti-
vated NF-kB and that this signaling pathway syn-
ergized with TNF-a to induce expression of various
proinflammatory genes (Fig. 7). Notably, EP2 and
TNF-a synergized in the expression of Ptgs2 at the
transcriptional level, and EP2 activation further
enhanced TNF-a–induced expression of Ccl2 post-
transcriptionally through HuR-mediated RNA sta-
bilization (Fig. 7). These findings suggest that the
COX-2–PGE2–EP2 signaling forms a positive feed-
back loop through the activation of NF-kB to amplify
and sustain inflammation. Enhanced MCP-1 abun-
dance in macrophages also amplifies inflammation
by recruiting more macrophages to the lesion. The
COX-2–PGE2–EP2 signaling in macrophages thus
functions as an inflammatory node in intracranial
aneurysm formation. Because the abundance of
both COX-2 and mPGES-1, an important enzyme
synthesizing PGE2 downstream of COX-2, is
increased in ruptured intracranial aneurysms from
human patients (43), this signaling cascade couldbe a promising target for drugs to treat intracranial aneurysms to pre-
vent not only their formation but also their rupture. Nonsteroidal anti-
inflammatory drugs (NSAIDs), such as COX inhibitors, may therefore
be good candidate drugs for intracranial aneurysm treatment. How-
ever, some case-control studies have reported that NSAIDs prevent
the rupture of intracranial aneurysms (which causes subarachnoid he-
morrhages) (44, 45), but others have reported that they facilitate the
rupture of these aneurysms (46). These discrepancies may be due to
the diverse actions of these types of drugs; they exert not only anti-
inflammatory actions but also anti-platelet actions, and some, particularly
selective COX-2 inhibitors, even increase cardiovascular risk (33).
NSAIDs have also considerable adverse effects, such as gastrointestinal
toxicity. These adverse effects would make it difficult to use NSAIDsA B
C
E F
D
Fig. 5. EP2 mediates stabilization of Ccl2 mRNA through HuR activation. (A) HEK293-EP2 cells were
stimulated with ONO-AE1-259, TNF-a, or both, and Ccl2 mRNA expression was examined by quantitative
RT-PCR (means ± SEM, n = 3 biological replicates, Kruskal-Wallis test). (B) Actinomycin D was added to
HEK293-EP2 cells stimulated with TNF-a and either vehicle or ONO-AE1-259. The decrease in Ccl2mRNA was
examined using quantitative RT-PCR (n = 5 biological replicates, Mann-Whitney test). (C to E) HEK293-EP2
cells transfected with the luciferase construct harboring the Ccl2 3′UTR were treated with ONO-AE1-259
using costimulation of IFN-g (IFN) and TNF-a, and luciferase activity was measured [(C), n = 4 biological
replicates]. The contribution of HuR binding to EP2-mediated stabilization of luciferase mRNA was examined
using Elavl1 (which encodes HuR)–targeted small interfering RNAs (siRNAs) [(D), nontarget siRNA and two
Elavl1-targeted siRNAs (siRNA #1 and siRNA #2), n = 4 biological replicates] and deletion of the HuR-binding
site [(E), del.HuR, n = 5 biological replicates, Kruskal-Wallis test]. (F) Binding of HuR to the Ccl2 3′UTR
examined by RNA immunoprecipitation with an antibody specific for HuR or IgG as a negative control in
HEK293-EP2 cells treated with either vehicle or ONO-AE1-259 (n = 4 biological replicates, Kruskal-Wallis test).8 of 17
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 as prophylactic drugs to control the macrophage-derived inflammatory
signals in intracranial aneurysms. Given the high incidence of intracranial
aneurysms in the general public and the severity of resultant subarachnoid
hemorrhage after rupture, more selective and safer alternatives to
NSAIDs or COX-2 inhibitors are therefore desired. The present study
demonstrated that administration of the selective EP2 antagonist PF-
04418948 significantly suppressed not only the development of intra-
cranial aneurysms but also the enlargement of preexisting intracranial
aneurysms in rats. In light of a large observational study conducted in
Japan that demonstrated that the annual rupture risk of unruptured in-Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017tracranial aneurysms positively correlates with size
(6), an EP2 antagonist is therefore a promising can-
didate to treat human intracranial aneurysms. Fur-
thermore, the rate of subarachnoid hemorrhage after
elastase-induced intracranial aneurysm (47) is increased
in mPGES-1–deficient mice, compared to wild-type
mice, although the incidence of intracranial aneurysms
is similar between the two genotypes. Aspirin, but not
PGE2, could ameliorate the increase in subarachnoid
hemorrhage (47), suggesting the involvement of a
PG or PGs other than PGE2 in the rupture of intra-
cranial aneurysm, which supports the potential supe-
riority of EP2 over mPGES-1 as a therapeutic target to
prevent rupture of intracranial aneurysms. However,
development of a selective EP2 antagonist to prevent
rupture of preexisting intracranial aneurysms will re-
quire the establishment of an animal model in which
intracranial aneurysms rupture more frequently.
Numerous previous studies using either human
tissue samples or animal models of intracranial an-
eurysms have shown that macrophages are major
inflammatory cells that infiltrate the intracranial
aneurysm lesions (19, 21, 22, 27, 48, 49). A role for
MCP-1 in macrophage recruitment in intracranial
aneurysm formation has been suggested by studies
using mice deficient in MCP-1 or rats in which
MCP-1 is inhibited with a dominant negative form
(19, 27). Here, we identified intracranial aneurysms
as a macrophage-mediated inflammatory disease of
intracranial arteries by demonstrating the crucial role
of the COX-2–PGE2–EP2–NF-kB–MCP-1 pathway
in macrophages in intracranial aneurysm formation.
This concept is pivotal not only for basic research
aimed at understanding the pathogenesis of intra-
cranial aneurysms but also for translational research
in applying these findings to the clinical setting, and
our results suggest the therapeutic value of targeting
this cell type in intracranial aneurysms. The selective
contribution of the COX-2 signaling pathway in
macrophages to the pathogenesis of vascular dis-
ease has also been demonstrated in atherogenesis,
in which macrophage-specific deletion of COX-2
ameliorates atherogenesis in hyperlipidemic mice
(50), suggesting that drugs targeting macrophages
can be used in other vascular diseases. Macrophage
activation may also be used as a surrogate marker of
inflammation in intracranial aneurysm walls to dis-
tinguish between rupture-prone intracranial aneur-
ysms and others with a lower probability of rupture.Our findings support those obtained from noninvasive MRI of macro-
phages in the intracranial aneurysm walls in patients administered
ultrasmall superparamagnetic iron oxide (USPIO) (51). This approach
thus allows for qualitative diagnosis of intracranial aneurysms before
surgical intervention and may thus be a breakthrough in the treatment
of intracranial aneurysms, because, currently, the annual rupture risk of
incidentally found intracranial aneurysms is estimated only from mor-
phological aspects, such as size or shape. Other confounding factors,
such as family history or racial background, also increase the risk of rup-
ture (5). As a corollary to the current clinical situation, small intracranialA
C
E
D
B
Fig. 6. Suppression of intracranial aneurysm development and enlargement by administration of
the EP2 antagonist PF-04418948 in rats through suppression of inflammatory responses. (A) Repre-
sentative images of Elastica van Gieson staining and quantitative measurement of intracranial aneu-
rysms in rats treated with the indicated doses of PF-04418948. Scale bars, 50 mm. a, maximum width in
the aneurysm wall; b, height of the aneurysm. The number of animals examined is shown in parentheses.
Statistical analysis was performed using a Kruskal-Wallis test. (B and C) Immunostaining for p-p65, COX-2,
and MCP-1 in rats with intracranial aneurysms treated with vehicle or PF-04418948 [(B), n = 3 rats for each
treatment] and the number of infiltrated macrophages found in intracranial aneurysm lesions [(C), n = 5 rats
for each treatment, Mann-Whitney test]. Scale bars, 50 mm. (D and E) One week after intracranial aneurysm
induction, rats were treated by oral administration of either vehicle (black line) or PF-04418948 (red line) for
the indicated periods. Intracranial aneurysm size was examined (D), and the number of infiltrated macro-
phages in the lesion was counted (E). The number of animals used is shown in parentheses. Statistical anal-
ysis was performed using a Mann-Whitney test.9 of 17
SC I ENCE S I GNAL ING | R E S EARCH ART I C L E
 o
n
 M
arch 17, 2017
http://stke.sciencem
ag.org/
D
ow
nloaded from
 aneurysms sometimes rupture before surgical treatment, and large intra-
cranial aneurysms with a low probability of rupture are surgically treated
with the risk of attendant complications. Further studies in humans will
be required to carefully examine whether MRI of macrophage infiltration
with USPIO reflects aneurysm enlargement or risk of rupture, and if in-
sufficient, imaging particles that provide higher resolution and contrast
should be developed. Using such a technique, we can envisage being able
to sequentially assess the inflammatory status in intracranial aneurysm
lesions in a less invasive manner and allow for the effect of investigational
drugs to be studied over a shorter period of time, which could greatly
facilitate the development of novel drugs to treat intracranial aneurysms.
In addition, macrophage-specific targeting of therapeutic drugs by apply-
ing this nanoparticle technique as a drug delivery vehicle may contribute
to the development of a safer and more effective drug therapy.
Chronic inflammation underlies various chronic intractable dis-
eases, such as cancer (52), vascular diseases including atherosclerosis
(53), autoimmune diseases, and neurodegenerative diseases. We sug-
gest that the PG system can contribute to the establishment of chronic
inflammation. In this model, PGs function synergistically with cytokines
and form a positive feedback loop to amplify and sustain inflammation
(9). Here, we found a positive feedback loop involving COX-2–PGE2–EP2–
NF-kB signaling in macrophages present in intracranial aneurysms. Fur-
thermore, the PGE2-EP2 signaling pathway functions as a “cytokine ampli-
fier” to amplify the TNF-a–induced expression of various inflammation-
associated genes, thereby exacerbating TNF-a–evoked inflammation. In
the case of Ptgs2 expression, the two pathways function together to facil-
itate the formation of the transcription factor complex including NF-kB
and Sp1, and in the case of Ccl2, PGE2-EP2 signaling stabilizes the Ccl2
mRNA encoding MCP-1 by activating HuR (Fig. 7), resulting in theAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017further amplification of macrophage accu-
mulation and macrophage-mediated in-
flammation. The PGE2-EP2 signaling
pathway in macrophages thus critically
contributes in amplifying and sustaining
inflammation in intracranial aneurysm le-
sions. In this sense, we can regard an intra-
cranial aneurysm as a chronic inflammatory
disease regulated by PGE2-EP2 signaling.
Presumably, this may be a common patho-
genesis in other chronic diseases; we have
found a similar amplifying loop involving
PGE2-EP2 signaling in colitis-associated
cancer (54). Therefore, the present findings
may contribute to our understanding of the
pathogenesis of various chronic inflamma-
tory diseases. EP4, but not EP2, signaling
facilitates disease progression, including
rupture of aortic aneurysm (55–57), and
thus, our results imply that the PG system
regulates disease pathogenesis through dif-
ferent receptor subtypes, presumably ac-
cording to their microenvironment.
A remaining question is how macro-
phages are recruited to the adventitia and
activated to initiate the formation of the in-
tracranial aneurysm lesions. Analysis from
the computational fluid dynamics field
suggests that high wall shear stress acts
on endothelial cells to trigger intracranialaneurysm formation (11). If macrophages in the adventitia come from
the blood, endothelial cells should be activated. NF-kB was activated
in endothelial cells of intracranial aneurysm walls at the early stage of
intracranial aneurysm formation (Fig. 2), and our previous study also
implicates EP2 signaling in this process (18). However, unexpectedly,
the present study revealed that both NF-kB activation and EP2
signaling in endothelial cells were dispensable for intracranial aneu-
rysm formation and macrophage-mediated inflammation in the lesion
(Figs. 2 and 3). These findings indicate that signaling through other
pathways is critically important for endothelial cell activation. Mechan-
otransduction mechanisms that sense hemodynamic force and convert it
to intracellular signaling in endothelial cells are an active research field,
and various mechanisms involving primary cilia, ion channels, integ-
rin, plasma membrane fluidity, or actin cytoskeleton are proposed as
components of the mechanosensing mechanisms (58). It will therefore
be important to discover the mechanism that senses hemodynamic stress
in endothelial cells that leads to subsequent macrophage infiltration.MATERIALS AND METHODS
Experimental design
For all animal studies, animals were randomized and investigators were
blinded to group allocation during data collection. At least three
independent samples were analyzed in all experiments.
Study approval
The animal experiments in this study complied with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use CommitteesPtgs2
PGE2
EP2
COX-2
PGE2
TNF-α
HuR
Positive feedback loop
Ptgs2
Ccl2
NF-κB
activation SP1
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Fig. 7. Proposed roles and mechanisms of PGE2-EP2 signaling to regulate chronic inflammation. EP2
signaling directly activates NF-kB and synergizes with TNF-a to induce expression of various proinflammatory
genes. For Ptgs2, this synergism occurs at the transcriptional level. For Ccl2, EP2 activation further enhances
TNF-a–induced expression of this gene posttranscriptionally through HuR-mediated RNA stabilization.10 of 17
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 of Kyoto University Graduate School of Medicine and RIKEN Kobe
Branch. A series of patient-derived tissue samples from 16 unruptured
and 20 ruptured intracranial aneurysms have been previously described
(20, 55). These tissue samples were collected during microsurgical clip-
ping of intracranial aneurysms at the Department of Neurosurgery,
Helsinki University Central Hospital, Helsinki, Finland. We obtained
informed consent from patients for their participation in the study after
the nature and possible consequences were explained; the study was ap-
proved by the Operative Ethical review committee of Helsinki Univer-
sity Central Hospital (approval number 21/13/03/02/2013).
Immunohistochemistry and immunofluorescence staining of
human intracranial aneurysm tissue samples
The detailed histopathology procedures performed on this set of
samples have been described previously (20, 59). Briefly, for immuno-
histochemistry, frozen sections (10 mm thick) were fixed, blocked, and
incubated with primary antibodies. Immune complexes were detected
with either a Vectastain Elite ABC kit (Vector Laboratories) or an EnVision
kit (DAKO) using 3,3′-diaminobenzidine as substrate. Sections were
costained with Mayer’s hematoxylin (Sigma-Aldrich) to visualize nuclei,
and in the case of CD68 immunostaining, sections were also costained
with Oil Red O. In negative controls, primary antibodies were either
omitted or replaced with an irrelevant IgG1 (Serotec). Resected human
tonsils and cadaver intracranial arteries served as positive controls.
Images were captured using a Zeiss Axioplan 2 imaging microscope
(Flokal Bv Micro-Optik) equipped with a ProgRes C7 USB digital cam-
era (Jenoptik).
For double immunofluorescence staining, frozen sectionswere fixed,
blocked with either 3% normal goat or 3% normal horse serum, and
incubated with primary antibodies, followed by detection with Alexa
488–conjugated anti-mouse, Alexa 594–conjugated anti-sheep, or
Alexa 594–conjugated anti-rabbit secondary antibodies (Molecular
Probes). The sections were mounted using a Vectashield medium with
DAPI (Vector Laboratories). An incubation omitting primary antibody
was used as the negative control. Immunofluorescence images were
captured with a 3DHISTECH Pannoramic 250 Flash II digital slide
scanner or an LSM700 Zeiss confocal microscope system. Maximum
intensity projections were generated from z sections using the ImageJ
program (https://imagej.nih.gov/ij/index.html). Primary antibodies
used were mouse monoclonal anti-human COX-2 antibody (DAKO),
rabbit polyclonal anti-human EP2 antibody (LifeSpan Biosciences Inc.),
mouse monoclonal anti-CD31 antibody (DAKO), mouse monoclonal
anti-CD68 antibody (DAKO), and mouse monoclonal anti–a–smooth
muscle actin antibody (Sigma-Aldrich).
Animals, rodent intracranial aneurysm models, and
histological analysis of induced intracranial aneurysm
Sprague-Dawley rats and C57BL/6NCrSlc mice were purchased from
Japan SLC. Lyz2-Cre transgenic mice and Cdh5-Cre transgenic mice
were purchased from The Jackson Laboratory. The Ptger2 flox mouse
line, NF-kB reporter mouse line, and IkB mutant transgenic mouse
line were established in the present study and deposited to RIKEN,
Japan (accession nos. CDB0939K, CDB0509T, and CDB0508T; www2.
clst.riken.jp/arg/mutant%20mice%20list.html; www2.clst.riken.jp/arg/
TG%20mutant%20mice%20list.html). Animals were maintained on a
light/dark cycle of 14 hours/10 hours under specific pathogen–free
conditions and had free access to chow and water.
Intracranial aneurysms were induced in 7-week-old male rats or
mice by ligation of the left common carotid artery followed by induc-Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017tion of systemic hypertension, which was achieved by salt overloading
and ligation of the left renal artery. Both surgeries were conducted un-
der general anesthesia induced by intraperitoneal injection of sodium
pentobarbital (50 mg/kg). This procedure, which is referred to as “in-
tracranial aneurysm induction” in this paper, is designed to increase
hemodynamic stress on bifurcation site of intracranial arteries in the
right, a contralateral side of the carotid ligation (8, 18). Immediately af-
ter intracranial aneurysm induction, animals were fed chow containing
8% sodium chloride and 0.12% 3-aminopropionitrile (#A0408, Tokyo
Chemical Industry), an inhibitor of lysyl oxidase, an enzyme that cata-
lyzes the cross-linking of collagen and elastin. 3-Aminopropionitrile was
used to facilitate intracranial aneurysm formation and progression by
exacerbating arterial wall fragility. Intracranial aneurysm induction
was assessed at the bifurcation of the right anterior cerebral artery
(ACA) and the olfactory artery (OA) at the indicated times in rats
and at 5 months in mice after induction, respectively. These sites were
chosen because intracranial aneurysm formation was found to be
consistent. Systolic, diastolic, and mean blood pressures were measured
using the tail-cuff method (BP-98A, Softron) without any anesthesia.
Systemic blood pressure measurements reported represent an average
of at least three independent measurements from each animal. For
histological analysis, animals were sacrificed after injection with a lethal
dose of sodium pentobarbital. Animals were transcardially perfused
with 4% paraformaldehyde, the ACA-OA bifurcation containing the
intracranial aneurysm was then dissected from the circle of Willis, and
5-mm-thick serial frozen sections were prepared. Some of the sections
were subjected to Elastica van Gieson staining to visualize the elastic lam-
ina in the intracranial aneurysm walls. An aneurysm was defined as a
lesion with disruption of the internal elastic lamina, as previously re-
ported (15, 18). The size of the induced intracranial aneurysms was
evaluated by a maximum transverse diameter as “Maximum” and a
height as “Height” using Elastica van Gieson–stained sections.
Generation of Ptger2 flox mouse line
A Ptger2 flox mouse was designed to delete exon 1 of the Ptger2 gene,
which encodes the first to sixth transmembrane domains, in the pres-
ence of Cre recombinase. Exon 1 of the Ptger2 gene was cloned using
PCR amplification from a BAC clone (#RP24-128I4 from BACPAC
Resources) as template and ligated in the DT-ApA/conditional KO FW
vector obtained from RIKEN (www2.clst.riken.jp/arg/cassette.html)
using the Pme I sites. The targeting vector was then injected into em-
bryonic stem (ES) cells, and after selection with neomycin and subse-
quent screening by PCR and Southern blot analyses, an ES cell line
with the expected homologous recombination was established. F0 mice
were then generated from ES clones and selected again by PCR and
Southern blot analyses. After the F1 strain containing the Ptger2 floxed
allele was selected by genotyping, the neomycin-resistant gene was
deleted by crossing these mice with FLP (flippase) transgenic mice to
establish the Ptger2flox/flox mouse strain (accession no. CDB0939K;
www2.clst.riken.jp/arg/mutant%20mice%20list.html). Correct ablation
of exon 1 of Ptger2 in the presence of Cre recombinase was confirmed
by direct sequencing analysis of offspring obtained from crossing the
Ptger2flox/flox line with the EIIa-Cre line (3130xl Genetic Analyzer
from Life Technologies Corporation).
Generation of cell type–specific Ptger2 knockout mice and
intracranial aneurysm induction
To generate macrophage- and endothelial cell–specific Ptger2-deficient
mice, Ptger2flox/flox mice were crossed with Lyz2-Cre and Cdh5-Cre11 of 17
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 transgenic mice (The Jackson Laboratory), respectively. Genotyping by
PCR was performed to detect the flox allele and the Cre gene using
KOD Plus DNA polymerase (Toyobo). Primer sets used in this step
were as follows: 5′-GCGGTCTGGCAGTAAAAACTATC-3′ (forward)
and 5′-GTGAAACAGCATTGCTGTCACTT-3′ (reverse) for the de-
tection of Cre; 5′-CACGGTTCCATTTCTTGGATGG-3′ (forward)
and 5′-TTCAGCTCTGAAGCCTTTAGCC-3′ (reverse) for the detec-
tion of the flox allele (wild-type allele, 243 bp; flox allele, 444 bp).
Generation of an NF-kB reporter mouse line and induction
of intracranial aneurysm
Six tandem NF-kB binding sites and a minimal promoter sequence
were inserted into the promoterless pTimer-1 vector from Clontech
Laboratories Inc. After confirming correct NF-kB–regulated expres-
sion of Timer-1 protein in vitro [stimulation with TNF-a (100 ng/ml)
for 24 hours] (fig. S3B), the vector was linearized and injected into
C57BL/6 fertilized eggs to generate transgenic mice. Offspring were
screened by genotyping using PCR analysis to detect the Timer-1 gene
using KOD Plus DNA polymerase (Toyobo) and the following primer
sets: 5′-GACGGCTGCTTCATCTACAAGG-3′ (forward) and 5′-
GTGATGTCCAGCTTGGTGTCC-3′ (reverse) (product size, 263 bp).
Regulated expression of Timer-1 protein under NF-kB–activating con-
ditions in this NF-kB reporter mouse line (accession no. CDB0508T;
www2.clst.riken.jp/arg/TG%20mutant%20mice%20list.html) was as-
sessed in LPS-induced hepatitis (20 mg/kg, 4 hours) (fig. S3C) or DSS-
induced colitis (fig. S3D).
Induction of intracranial aneurysms was performed in these dif-
ferent mouse lines, as described previously. At the indicated times
after surgical induction, mice were sacrificed and 5-mm-thick slices
from the walls of the intracranial aneurysm were prepared as de-
scribed previously. NF-kB activation in intracranial aneurysm walls
was examined by immunohistochemical detection of the Timer-1 pro-
tein with an antibody recognizing RFP (Rockland Immunochemicals
Inc.). To evaluate the type of cells in which NF-kB was activated, dou-
ble immunostaining was performed using both an antibody that re-
cognizes RFP and an antibody for each cell marker: for endothelial
cells, a rat monoclonal antibody recognizing mouse CD31 (BD Bio-
sciences); for smooth muscle cells, a mouse monoclonal antibody rec-
ognizing human a–smooth muscle actin (Thermo Fisher Scientific);
and for macrophages, a rat monoclonal antibody recognizing F4/80
(Abcam).
Generation of a Ptger2-deficient NF-kB reporter mouse line
To examine the effects of Ptger2 deficiency on NF-kB activation in
vivo, we generated a Ptger2-deficient NF-kB reporter transgenic
mouse line by crossing Ptger2-deficient mice with NF-kB reporter
mice. Offspring were screened by genotyping in PCR analysis to detect
both the absence of the Ptger2 allele and the presence of Timer-1 gene
using a KOD Plus DNA polymerase (Toyobo) and the primer sets
described previously.
Generation of conditional IkB mutant transgenic mouse line
and intracranial aneurysm induction
The mouse IkBa gene was cloned by PCR using complementary DNA
(cDNA) prepared from total RNA purified from mouse kidney, and
its sequence was confirmed by sequencing. Site-directed mutations at
two serine residues (S32A and S36A) in the IkBa gene were generated
using a KOD Plus Mutagenesis kit (Toyobo). Mutated IkBa was then
fused in-frame with the mCherry gene to allow monitoring of the IkBAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017mutant protein expression and then cloned into the pCCALL2 vector,
which contains the loxP-stop-loxP sequence under the transcriptional
control of the CAG promoter. After in vitro confirmation of the regu-
lated expression of the mutated IkBa–mCherry fusion protein under the
control of Cre recombinase, resistance to TNF-a (100 ng/ml, 20 min)–
induced degradation (fig. S8B), and also potent inhibitory capability of
NF-kB activation under stimulation with TNF-a (100 ng/ml, 20 min)
(fig. S8C), the vector harboring the mutated IkBa–mCherry construct
was linearized and injected into C57BL/6 fertilized eggs. Proper inte-
gration of the transgene into the mouse genome was confirmed by
genotyping and also by Southern blot analysis. From this, we obtained
four independent lines of loxP-stop-loxP–IkB mutant–mCherry con-
ditional transgenic mice. The regulated expression of the mutated
IkBa–mCherry fusion protein in the presence of Cre recombinase
was assessed in these mice (accession no. CDB0509T; www2.clst.riken.
jp/arg/TG%20mutant%20mice%20list.html) by transfecting primary
cultures of macrophages obtained from either the intraperitoneal cav-
ity or the femoral muscle with a Cre recombinase expressing plasmid
(48 hours) (fig. S8, D and E).
To establish endothelial cell– or macrophage-specific IkB mutant–
mCherry fusion protein–expressing mice, loxP-stop-loxP–IkB mutant–
mCherry conditional transgenic mice (line #12) were crossed with
Cdh5-Cre or Lyz2-Cre transgenic mice line (The Jackson Laboratory),
respectively. Offspring were then genotyped by PCR screening to detect
the flox allele and the Cre gene using a KOD Plus DNA polymerase
(Toyobo). The primer sets used were as follows: 5′-GCGGTCTGGCAG-
TAAAAACTATC-3′ (forward) and 5′-GTGAAACAGCATTGCTGTC-
ACTT-3′ (reverse) to detect Cre; 5′-GCCAAGCTGAAGGTGACCAAGG-3′
(forward) and 5′-GCTTCAGCCTCTGCTTGATCTCG-3′ (reverse) to
detect the IkB mutant–mCherry sequence (product size, 370 bp). Mice
for each genotype were obtained in the expected Mendelian ratios.
Southern blot analysis
Southern blot analysis was performed to confirm the correct recom-
bination of the genome of genetically modified mice (figs. S5B and
S7C). Briefly, mouse genomic DNA was purified from the kidney of
each mouse line and digested with restriction enzymes Swa I, Sca I,
Bgl II, or Eco RV for at least 48 hours until complete digestion was
confirmed by electrophoresis. Digested DNA (50 mg) was then sep-
arated by electrophoresis on a 0.5% agarose gel, transferred to a
nylon membrane (Hybond-N, GE Healthcare), and hybridized with
digoxigenin-labeled probes generated by in vitro transcription (DIG
High Prime DNA Labeling and Detection Starter Kit II, Roche Diag-
nostics). Probe locations within the genome are indicated in the map
of each mouse line. Signal was detected using a chemiluminescence
reagent (CDP-Star, Roche).
RNA extraction from in vivo samples and quantitative
RT-PCR analysis
Five months after intracranial aneurysm induction, animals were sac-
rificed. Total RNA was purified from the anterior portion of the circle
of Willis and reverse-transcribed into cDNA using an RNeasy Fibrous
Tissue Mini kit (Qiagen) and a High-Capacity cDNA Reverse Tran-
scription kit (Life Technologies) according to the manufacturer’s in-
structions. Quantitative RT-PCR analysis was then performed with a
SYBR Premix Ex Taq II kit (Takara) and a Real-Time System CFX96
(Bio-Rad). Actb (which encodes b-actin) was used as an internal con-
trol [primer sets: 5′-ACGACCAGAGGCATACAGGGA-3′ (forward)
and 5′-CCCTAAGGCCAACCGTGAAA-3′ (reverse)]. For quantification,12 of 17
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 the second derivative maximum method was used for crossing point
determination, and the value of each gene expression was normalized
to Actb expression. Primer sets used in the RT-PCR were as follows:
5′-GTCTCTGCCGCCCTTCTGTG-3′ (forward) and 5′-AGGT-
GACTGGGGCATTGATTG-3′ (reverse) for mouse Ccl2; 5′-
CTTCTGCAGTCCAGGTTCAATGG-3′ (forward) and 5′-AAGA-
CTTGCCAGGCTGAACTTCG-3′ (reverse) for mouse Ptgs2; and
5′-CCAAGACAAGGAAGGTTAGGC-3′ (forward) and 5′-GGAAGT-
ATTTGGCTCCATTCC-3′ (reverse) for rat Sp1.
Immunohistochemistry of tissue specimens
Immunohistochemistry was performed as previously described (18).
Briefly, at 1, 2, 4, 8, 20, 27, and 32 weeks in mice or at 3, 4, or 6 weeks
in rats after intracranial aneurysm induction, animals were sacrificed
and perfused transcardially with 4% paraformaldehyde. The right
ACA-OA bifurcation was then dissected from the circle of Willis,
and 5-mm-thick tissue sections were prepared. In some analyses, tis-
sues from other organs, namely, spleen, lung, aorta, and kidney, were
dissected and similar tissue slices were made. After blocking the tissue
slices with 5% donkey serum (Jackson ImmunoResearch), primary
antibodies diluted in phosphate-buffered saline were incubated with
the slices, followed by incubation with secondary antibodies conjugated
with a fluorescent dye (Jackson ImmunoResearch). Fluorescent images
were acquired using a CTR6500 confocal fluorescence microscope
(Leica Microsystems). Cells positive for F4/80 in mice or CD68 in rats
by immunohistochemistry were defined as macrophages. The number
of infiltrated macrophages found within a 100-mm square around the
dome of the induced aneurysms was calculated.
Primary antibodies used were as follows: a rat monoclonal anti-
body recognizing mouse CD31 (BD Biosciences), a mouse monoclo-
nal antibody recognizing human a–smooth muscle actin (Thermo
Fisher Scientific), a rat monoclonal antibody recognizing F4/80 (Abcam),
a mouse monoclonal antibody recognizing CD68 (Abcam), a rabbit
polyclonal antibody recognizing RFP (Rockland Immunochemicals),
a rabbit monoclonal antibody recognizing the phosphorylated form
of NF-kB p65 (Ser536) (Cell Signaling Technology), a rabbit polyclonal
antibody recognizing Cre (Merck Millipore), a goat polyclonal anti-
body recognizing MCP-1 (Santa Cruz Biotechnology), and a rabbit
polyclonal antibody recognizing COX-2 (Cayman Chemical).
DSS-induced colitis in mice
Experimental colitis was induced in mice by oral administration of
DSS (molecular weight, 36,000 to 50,000; MP Biomedicals LLC).
DSS was given to mice in drinking water (3%) for 8 days followed
by 3-day administration with normal drinking water. Eleven days after
the start of DSS treatment, mice were sacrificed and the colon was
dissected for analysis.
EP2 antagonist treatment
PF-04418948, 1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl}
azetidine-3-carboxylic acid, a selective EP2 antagonist with a Ki value
of 16 nM for human EP2 (41), was synthesized at KNC Laboratories
Co. Ltd. The purity of synthesized PF-04418948 was 99.1% by high-
performance liquid chromatography. PF-04418948 was orally admin-
istered to rats by mixing it into chow to provide the doses indicated
(1, 3, 10, and 50 mg/kg) for 3 weeks. In some experiments, the intra-
cranial aneurysm was first induced in rats for 1 week after surgical
manipulation, and then, PF-04418948 (50 mg/kg) was administered
daily for an additional 5 weeks.Aoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017Microarray analysis
Three weeks after intracranial aneurysm induction, rats were sacrificed.
Total RNA was purified from the right anterior portion of the circle of
Willis using an RNeasy Fibrous Tissue Mini kit (Qiagen). Purified
RNA was then labeled with the fluorescent dye Cy3 using a Low Input
Quick Amp Labeling Kit, One-Color (Agilent Technologies) and hy-
bridized to array plates (SuperPrint G3 rat GE 8X60K Microarray,
Agilent Technologies) using a Gene Expression Hybridization kit
(Agilent Technologies). After washing the hybridized array, signals
were detected using a microarray scanner (Agilent Technologies).
Data were analyzed using the GeneSpring software (Agilent Technol-
ogies). The fold changes in expressions of each gene in the intracranial
aneurysm lesions were calculated as a ratio compared to that in the
ring of Willis from sham-operated rats.
Compounds used in in vitro experiments
Cultured cells were treated with the following compounds, as indi-
cated in Materials and Methods, the figure legends, and figures: LPS
(Sigma-Aldrich), EP2 agonist (ONO-AE1-259, gift from Ono Phar-
maceutical Co. Ltd.), TNF-a (R&D Systems), IFN-g (R&D Systems),
H-89 (Merck KGaA), SB202190 (Merck KGaA), SB239063 (Merck
KGaA), mithramycin A (Santa Cruz Biotechnology), leptomycin B
(Merck KGaA), and NF-kB inhibitor IV (Merck KGaA).
Generation of a HEK293 cell line stably expressing EP2
The open reading frame (ORF) of mouse Ptger2 was obtained by PCR
using PrimeSTAR Max DNA polymerase (Takara), and its sequence
was confirmed. The ORF of Ptger2 was then cloned into the pLenti6.3
vector containing the blasticidin resistance gene as a selection marker
(Life Technologies). Subsequently, Lenti-X cells were transfected with
the pLenti6.3-murine Ptger2 plasmid and packaging plasmids (Clontech)
to generate lentiviral particles harboring Ptger2, which were used to
infect HEK293 cells. The pLenti6.4-GFP plasmid was used as a control
to monitor infection efficiency. Finally, infected HEK293 cells were
selected for resistance to blasticidin for 120 hours to establish the
HEK293 cell line stably expressing EP2 (HEK293-EP2) (fig. S12A).
The concentration of blasticidin used was 6 mg/ml because this dose
killed all noninfected cells. To functionally validate the established
HEK293-EP2 cell line, the cells were stimulated with the selective EP2
agonist ONO-AE1-259 [median effective concentration (EC50), 0.003 mM]
(0.00005, 0.005, and 0.5 mM for 15 min) (28), and dose-dependent in-
creases in cAMP were measured using a Cyclic AMP EIA kit (Cayman
Chemical) according to the manufacturer’s instructions (fig. S12C).
In RT-PCR experiments, cells were stimulated with ONO-AE1-259
(0.5 mM), TNF-a (1 ng/ml), or both agents in combination for 1, 2, or
3 hours, and total RNA was isolated for further analysis (Fig. 5A and
figs. S13D and S15A). To examine the role of posttranscriptional
modifications on Ccl2 or Ptgs2 mRNA induction after EP2 stimula-
tion, actinomycin D (20 mg/ml) and 0.5 mMONO-AE1-259 were added
to cells prestimulated with TNF-a (100 ng/ml) for 2 hours, and the
decrease in Ccl2 or Ptgs2 mRNA levels was examined by RT-PCR
(Fig. 5B and fig. S17A).
Generation of an NF-kB reporter HEK293 cell line
The kB-GFP cassette was transduced into HEK293 cells using the
lentivirus system (Cignal Lenti Reporter Assay, Qiagen) according
to the manufacturer’s instructions, and infected cells were cloned by
selection in puromycin (1600 ng/ml) for 2 weeks. The effect of the
EP2 agonist ONO-AE1-259 (0.5 mM, 24 hours) on NF-kB activation13 of 17
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 was examined by assessing GFP expression using TNF-a stimulation
(100 ng/ml, 24 hours) as a positive control (fig. S13A).
Preparation of macrophage primary cultures
Primary macrophages were obtained from the intraperitoneal cavity of
rats that had been injected intraperitoneally with a 3% thioglycollate
broth. After 4 days, the peritoneal cavity was washed with ice-cold
RPMI 1640 medium supplemented with 10% fetal bovine serum
and cells resident in the peritoneal cavity were collected. After washing,
the cells were seeded in culture dishes and indomethacin (100 mM,
2 hours) was added to inhibit endogenous PGE2 production before
cells were used in in vitro experiments. Cells were then stimulated
with ONO-AE1-259 (0.5 mM, 2 hours) or TNF-a stimulation (1 ng/ml,
2 hours) or a combination of both agents (Fig. 4D). In some exper-
iments, macrophages were treated with NF-kB inhibitor IV (50 mM)
and ONO-AE1-259 (0.5 mM, 1 hour) with or without TNF-a stimu-
lation (5 ng/ml, 1 hour) (fig. S14D).
Quantitative RT-PCR analysis in cultured cells
RNA purification from cultured cells and reverse transcription of puri-
fied RNA were performed using an RNeasy Mini kit (Qiagen) and a
High-Capacity cDNA Reverse Transcription kit (Life Technologies
Corporation), according to the manufacturers’ instructions. For quan-
tification of gene expression, RT-PCR was performed on Real-Time Sys-
tem CFX96 (Bio-Rad) using SYBR Premix Ex Taq II (Takara). Actb was
used as the internal control. For quantitation, the second derivative
maximum method was used for crossing point determination.
Primers used were as follows: 5′-CATACTCCTGCTTGCTGATCC-
3′ (forward) and 5′-GATGCAGAAGGAGATCACTGC-3′ (reverse) for
human Actb; 5′-ACACCCTCTATCACTGGCATCC-3′ (forward) and
5′-AACATTCCTACCACCAGCAACC-3′ (reverse) for human Ptgs2;
5′-AGCTTCTTTGGGACACTTGC-3′ (forward) and 5′-ATAGCAGC-
CACCTTCATTCC-3′ (reverse) for human Ccl2; 5′-CTGTTGCCCAT-
CAACGGTCTG-3′ (forward) and 5′-AATGGCAGCAATGGC-
AGTGAG-3′ (reverse) for human Sp1; 5′-ACATGGTCATGGTCAAA-
GAGG-3′ (forward) and 5′-TTGTAAGTCACCGCCAGTACC-3′ (re-
verse) for human Elavl1; 5′-GGGCAGTAATCTCCTTCTGCATCC-3′
(forward) and 5′-TTCCTGGGTATGGAATCCTGTGG-3′ (reverse) for
rat Actb; 5′-GATGTGGATGCTTTCAAGTCC-3′ (forward) and 5′-
CCTGTGAGCAGTCAGAGAAGG-3′ (reverse) for rat Fos; 5′-ACTAG-
CAGGTCGTCATCATCC-3′ (forward) and 5′-CATCTCGACAAGA-
GCTTCAGG-3′ (reverse) for rat Il1b; 5′-TCCTTTCCAGGTCAGT-
TAGCC-3′ (forward) and 5′-GCCCAGACAGAAGTCATAGCC-3′ (re-
verse) for rat Cxcl2; 5′-CCGGACTTGTGAAGTAGGGAAGG-3′
(forward) and 5′-CCACCAGGAACGAAAGTCAACTCC-3′ (reverse)
for rat Il6; 5′-TCAGTATGAGCCTGCTGGTTTGG-3′ (forward) and
5′-CCGGGTCTGATGATGTATGCTACC-3′ (reverse) for rat Ptgs2;
and 5′-GTCAGAGTCTTGTGCCTTTGG-3′ (forward) and 5′-CCA-
AGCTGAACTTGAGTGAGG-3′ (reverse) for rat Nos2.
Luciferase assays
A luciferase assay was used to examine the promoter activity of Ptgs2,
the transcriptional activity of Sp1 and NF-kB, or the effect of the 3′
UTR of Ccl2 mRNA on mRNA stabilization. Luciferase activity was
measured using the Dual-Luciferase Reporter Assay System and the
GloMax Microplate Luminometer (Promega) according to the manu-
facturer’s instructions. Constructs used in these experiments were gen-
erated by ligating a PCR-amplified fragment of the gene promoter of
interest into the multicloning site of the pGL4.17 vector harboring theAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017ORF of firefly-luciferase (Promega). The Sp1 reporter construct was
made by ligating, in tandem, three consensus Sp1 binding sites along
with the minimum promoter upstream of the firefly-luciferase ORF.
To establish the NF-kB reporter in HEK293 cells, the NF-kB–firefly-
luciferase cassette and the control Renilla-luciferase cassette were
transduced into HEK293 cells using the lentivirus system (Cignal
Lenti Reporter Assay) according to the manufacturer’s instructions,
and infected clones were selected using puromycin (1600 ng/ml, 2
weeks). To examine mRNA stabilization by the RNA binding protein
HuR, the 3′UTR of human CCL2 mRNA was cloned [using the
following primer set: 5′-ACACTCACTCCACAACCCAAG-3′ (forward)
and 5′-TTTGGTGTAATAGTTACAAAA-3′ (reverse)] and ligated into
the 3′ end of the firefly-luciferase ORF driven under the transcriptional
control of the PGK (phosphoglycerate kinase) promoter (Promega).
Site-directed mutagenesis or construct deletion was achieved using
an inverse PCR–based method using a KOD Plus Mutagenesis kit
(Toyobo). Some mutants were constructed by restriction enzyme diges-
tion of the original construct and self-ligation. In these experiments, a
Renilla-luciferase construct driven by the TK (thymidine kinase) promoter
(Promega) cotransfected with the firefly-luciferase construct was used
as the internal control.
In the luciferase assay, to examine the transcriptional regulation of
Ptgs2 by EP2 and TNF-a signaling, cells transfected with a construct
harboring the Ptgs2 promoter sequence or its mutants were stimulated
with ONO-AE1-259 (0.005 or 0.5 mM, 6 hours) or TNF-a (1 ng/ml,
6 hours) (Fig. 4E and fig. S15, B and C). To examine the transcrip-
tional activity of Sp1, HEK293-EP2 cells were transfected with the Sp1
reporter firefly-luciferase plasmid and control Renilla-luciferase plas-
mid and stimulated with ONO-AE1-259 (0.5 mM) or TNF-a (1 ng/ml)
or in combination for 2, 6, and 24 hours (fig. S16B). To further exam-
ine the effect of Sp1 on Ptgs2 promoter activity, cells treated with the
Sp1 inhibitor mithramycin (0.1, 0.5, or 1 mM) or transfected with siRNA
to deplete Sp1 or an Sp1-overexpressing plasmid were stimulated
with ONO-AE1-259 (0.5 mM) or TNF-a (1 ng/ml) or in combination
for 6 hours (fig. S16, B to E). To examine the effect of EP2 signaling on
stabilization of Ccl2 mRNA, HEK293-EP2 cells transfected with the
luciferase-Ccl2-3′UTR construct or its mutants were treated with 0.5 mM
ONO-AE1-259 alone for 12 hours or in combination with the p38 in-
hibitor SB202190 (0.1 or 1 mM), SB239063 (1 or 10 mM), or leptomycin
B (0.4, 4 or 40 nM) and analyzed by luciferase assay (Fig. 5, C to E, and
fig. S17D). To examine the effect of NF-kB inhibitor IV on NF-kB tran-
scriptional activity, NF-kB reporter HEK293 cells were treated with
each dose of NF-kB inhibitor IV in combination with TNF-a stimula-
tion (10 ng/ml, 6 hours) (fig. S14C).
Immunohistochemistry and Western blot analysis using
in vitro samples
For immunohistochemistry, cells were cultured on chamber slides and,
in some experiments, stimulated with compounds [ONO-AE1-259:
0.5 mM, 24 hours; TNF-a: 100 ng/ml, 20 min (fig. S8B) or 24 hours
(fig. S3B)]. Cells were then fixed with 4% paraformaldehyde. After
blocking with 5% donkey serum (Jackson ImmunoResearch), samples
were incubated with primary antibodies, followed by incubation
with secondary antibodies conjugated with a fluorescent dye (Jackson
ImmunoResearch). Fluorescent images were acquired on a confocal
fluorescence microscope system (CTR6500, Leica Microsystems).
For Western blot analysis, whole-cell lysates were prepared from
treated cells (ONO-AE1-259: 0.00005, 0.005, or 0.5 mM for 20 min
and 0.5 mM for 20, 60, 120, or 240 min; db-cAMP: 30 or 100 mM for14 of 17
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 20 min; H-89: 1 or 10 mM for 20 min; TNF-a: 1 ng/ml for 20 min;
LPS: 1 mg/ml for 30 min) (Fig. 4, B and C, and figs. S13B, S14A, and
S18B) by adding RIPA solution supplemented with proteinase and phos-
phatase inhibitors (Sigma-Aldrich). In some experiments, cytoplasmic
and nuclear fractions were prepared separately using a Nuclear Extrac-
tion kit (Active Motif), from HEK293-EP2 cells treated with 0.5 mM
ONO-AE1-259 for 8 hours (fig. S17C) or RAW264.7 cells (purchased
from Public Health England) stimulated with LPS (1 mg/ml, 20 min)
in the presence or absence of NF-kB inhibitor IV (50 mM) (fig. S14B),
and nuclear and cytosolic extracts were prepared according to the man-
ufacturer’s instructions. After SDS–polyacrylamide gel electrophoresis
of the nuclear and cytoplasmic fractions (20 mg), proteins were trans-
ferred to a polyvinylidene difluoride membrane (Hybond-P, GE Health-
care) and blocked with ECL Plus blocking agent (GE Healthcare). The
blotted membranes were then incubated with primary antibodies
followed by incubation with horseradish peroxidase–conjugated IgG
(GE Healthcare). Finally, signals were detected using chemiluminescence
(ECL Prime Western Blotting Detection System, GE Healthcare). a-
Tubulin (total cell lysate and cytoplasm) or lamin B (nuclear) served as
an internal control.
Primary antibodies used were as follows: a rabbit monoclonal
antibody recognizing p65 (Cell Signaling Technology), a rabbit mono-
clonal antibody recognizing a phosphorylated form of NF-kB p65
(Ser536) (Cell Signaling Technology), a rabbit monoclonal antibody
recognizing the phosphorylated form of NF-kB p105 (Ser337) (Cell
Signaling Technology), a mouse monoclonal antibody recognizing IkBa
(Cell Signaling Technology), a rabbit monoclonal antibody recognizing
p38 (Cell Signaling Technology), a rabbit monoclonal antibody recog-
nizing the phosphorylated form of p38 (Thr180/182) (Cell Signaling
Technology), a rabbit monoclonal antibody recognizing TBP (TATA-
binding protein) (Cell Signaling Technology), a mouse monoclonal
antibody recognizing a-tubulin (Sigma-Aldrich), a rabbit polyclonal
antibody recognizing EP2 (Cayman Chemical), a goat polyclonal
antibody recognizing lamin B (Santa Cruz Biotechnology), a mouse
monoclonal antibody recognizing HuR (Santa Cruz Biotechnology), a
rabbit polyclonal antibody recognizing RFP (Rockland Immunochem-
icals), a rat monoclonal antibody recognizing GFP (Nacalai Tesque
Inc.), and a rabbit polyclonal antibody recognizing Sp1 (Merck Millipore)
Transfections
All plasmid transfections in cultured cells were performed using a
liposome-based method (FuGENE, Promega). Cells were harvested
and analyzed at least 24 hours after transfection.
PCR array analysis
PCR array analysis was performed according to the manufacturer’s
instructions (SABioscience, Qiagen) (Fig. 4D). Briefly, total RNA from
primary cultures of intraperitoneal macrophages with TNF-a alone
(5 ng/ml, 1 hour) or in combination with ONO-AE1-259 (0.5 mM) was
purified using an RNeasy Plus Mini kit and subsequently reverse-
transcribed using an RT2 First Strand kit (Qiagen). PCRs were per-
formed using RT2 qPCR Master Mix on Real-Time System CFX96
(Bio-Rad) according to the manufacturer’s instructions. Finally, the
relative expression of each gene was calculated and compared using
the five internal controls supplied by the manufacturer.
RNAi in cultured cells
Cultured cells were transfected with commercially available prede-
signed Stealth siRNAs (Sp1, 10 nM; Elavl1, 30 nM) or a scrambledAoki et al., Sci. Signal. 10, eaah6037 (2017) 7 February 2017siRNA using Lipofectamine RNAi MAX (Life Technologies) and cul-
tured for an additional 72 hours to achieve sufficient knockdown (Fig.
5D and figs. S16D and S17B). The efficiencies of target mRNA and
protein depletions were confirmed by quantitative RT-PCR analysis
and Western blotting, respectively, using three independent biological
replicates.
Cloning and overexpression of Sp1
The ORF of the human Sp1 gene (NM_138473.2) was prepared by
PCR from cDNA prepared from HEK293 cells using the primers
5′-GTTCGCTTGCCTCGTCAG-3′ (forward) and 5′-AATGCTTCA-
TGGCTCTCTCTTC-3′ (reverse) and cloned into the pcDNA3 vector.
ChIP and Re-ChIP assay
ChIP and Re-ChIP assays were performed according to the manufac-
turer’s instructions using an EZ-Magna ChIP kit (Merck Millipore)
and a Re-ChIP-IT kit (Active Motif). Cells were stimulated with either
TNF-a (1 ng/ml) or 0.5 mM ONO-AE1-259 or both for 90 min and
subjected to ChIP or Re-ChIP assays (Fig. 4, F and G). Antibodies used in
these experiments were a mouse monoclonal antibody recognizing
p65 (Merck Millipore) and a rabbit polyclonal antibody recognizing
Sp1 (Merck Millipore). Primer sets used to detect the immunopreci-
pitated promoter fragments were as follows: 5′-AAAGACATCTGGC-
GGAAACC-3′ (forward) and 5′-AAATCGGAAACCCAGGAAGC-3′
(reverse) for the proximal NF-kB site; 5′-AAGACGTACAGACCA-
GACACG-3′ (forward) and 5′-CAGAAGGACACTTGGCTTCC-3′
(reverse) for the distal NF-kB site; and 5′-TTACCTTTCCCGCCT-
CTCTTTCC-3′ (forward) and 5′-GTGACGACGCTTAATAGGCTG-3′
(reverse) for the Sp1 site in the Ptgs2 promoter.
DNA binding activity of transcription factors
The DNA binding activities of each NF-kB subunit (p50, p65, and
c-Rel) and Sp1 were assessed in cultured cells (ONO-AE1-259: 0.5 mM,
20 min; TNF-a: 100 ng/ml, 20 min) (Fig. 4A and figs. S13C and S16A)
or after intracranial artery aneurysm induction (1 month) (fig. S16F)
according to the manufacturer’s instructions.
Detection of MAPK phosphorylation by Proteome
Profiler Array
HEK293-EP2 cells were stimulated with ONO-AE1-259 (0.5 mM,
20 min), and whole-cell lysates were prepared (fig. S18A). Phospho-
rylation of each MAPK member was then detected in lysates (300 mg)
using a Proteome Profiler Human Phospho-MAPK Array kit (ARY002
from R&D Systems) according to the manufacturer’s instructions.
RNA immunoprecipitation analysis
RNA immunoprecipitation analyses were performed using a Magna
RIP RNA-Binding Protein Immunoprecipitation kit (Merck Millipore)
according to themanufacturer’s instructions (Fig. 5F). Briefly,HEK293-
EP2 cells were stimulated with ONO-AE1-259 (0.5 mM, 8 hours), and
whole-cell lysates were prepared. RNA bound with HuR was then im-
munoprecipitated using a mouse monoclonal anti-HuR antibody
(Santa Cruz Biotechnology) or normal mouse IgG as a negative con-
trol. RNAwas purified from the immunoprecipitate and then reverse-
transcribed into cDNA. Finally, enrichment of the 3′UTR of Ccl2 was
assessed using quantitative RT-PCR. The sequences of primers used
for detecting 3′UTR of Ccl2 mRNA were 5′-AGCAATTTCCC-
CAAGTCTCTG-3′ (forward) and 5′-ACCCAAGAATCTGCAGC-
TAAC-3′ (reverse).15 of 17
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Data were shown as means ± SEM. Differences between the two
groups were examined using the nonparametric Mann-Whitney
test. Statistical comparisons between more than two groups were
conducted using Kruskal-Wallis test followed by the post hoc Steel test.
The incidence of intracranial aneurysm across groups was analyzed
using Fisher’s exact test. Correlations between continuous and ordinal
variables were examined using Spearman’s rank correlation test. Nom-
inal data were statistically compared using Fisher’s exact test or the c2
test, as appropriate. o
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Fig. S1. Scoring of COX-2 and EP2 abundance in human intracranial aneurysm lesions.
Fig. S2. Immunostaining for EP2, CD31, and/or a–smooth muscle actin in human intracranial
aneurysm lesions.
Fig. S3. Verification of the NF-kB reporter construct.
Fig. S4. NF-kB activation in intracranial arterial wall during intracranial aneurysm development
assessed in NF-kB reporter mice.
Fig. S5. Generation of the Ptger2flox/flox mouse line.
Fig. S6. Effect of macrophage-specific deletion of Ptger2 on MCP-1 and COX-2
immunofluorescence in intracranial aneurysm lesions.
Fig. S7. Generation of the IkB mutant transgenic mouse line.
Fig. S8. Cre-dependent expression of the IkB mutant and suppression of NF-kB activation.
Fig. S9. Generation of transgenic mouse lines expressing a macrophage-specific IkB mutant–
mCherry fusion protein.
Fig. S10. Generation of transgenic mouse lines expressing IkB mutant–mCherry fusion protein
in an endothelial cell–specific fashion.
Fig. S11. Effects of macrophage- and endothelial cell–specific expression of the IkB mutant
protein on systemic blood pressure and macrophage recruitment after intracranial aneurysm
induction.
Fig. S12. Generation of the HEK293-EP2 cell line.
Fig. S13. NF-kB activation in response to EP2 signaling in HEK293-EP2 cells.
Fig. S14. Involvement of NF-kB activation in amplifying the effect of EP2 on TNF-a–induced
gene expression.
Fig. S15. Analysis of the Ptgs2 gene promoter for kB sites responsive to EP2 and TNF-a
signaling.
Fig. S16. Activation of Sp1 by TNF-a signaling in HEK293-EP2 cells.
Fig. S17. EP2-induced HuR translocation.
Fig. S18. Activation of the MAPK p38 by EP2 signaling in HEK293-EP2 cells.
Fig. S19. Effects of PF-04418948 on systemic blood pressure and thinning of media in
intracranial aneurysm walls.
Table S1. Gene expression analysis of rat intracranial aneurysm lesions.
Data file S1. Full gene list from microarray analysis of rat intracranial aneurysm lesions. 017REFERENCES AND NOTES
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